Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTX-712
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Theradex
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTX-712 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : CTX-712
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Theradex
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTX-712 is a first-in-class, orally available and selective small molecule inhibitor of CDC-like kinase (CLK), a key regulator of the RNA splicing process that plays an important role in cell growth.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : CTX-177
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ono Pharmaceutical
Deal Size : $509.7 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Chordia will grant exclusive rights to develop, manufacture and commercialize CTX-177 and other related compounds globally.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : CTX-177
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ono Pharmaceutical
Deal Size : $509.7 million
Deal Type : Collaboration
Reset All
